The cash premium offers immediate realized value with high probability of closing given committed financing and no financing condition. Monitor the June 22 HSR deadline and shareholder vote timing. The 3.8% termination fee is below the 3-4% standard for mid-cap pharma, making a competing bid plausible but unlikely given the active market check process
Price Chart
Executive Summary
Catalyst Pharmaceuticals (CPRX) filed a preliminary proxy statement (PREM14A) seeking stockholder approval for its acquisition by Angelini Pharma at $31.50 per share in cash, a transaction valued at approximately $4.1 billion. The board unanimously recommends the deal, which includes a 28% premium to the 30-day VWAP and follows the resolution of all FIRDAPSE patent litigation with Hetero agreeing not to launch a generic before January 2035.
Key Financial Metrics
Key Facts
- Merger consideration: $31.50 per share in cash (28% premium to 30-day VWAP, 21% premium to unaffected close of $25.94)
- Total equity value: approximately $4.1 billion
- Board unanimously recommends voting FOR the merger proposal
- J.P. Morgan fairness opinion: consideration is fair from a financial point of view
- All executive officers and directors (~10% of outstanding shares) have signed voting agreements to vote FOR the merger
- HSR waiting period expires June 22, 2026; merger expected to close in Q3 2026
- Termination fee: $155,475,048 (~3.8% of equity value)
- Angelini Pharma has $3.99B in committed debt financing from BNP Paribas; financing is not a condition to closing
- All outstanding in-the-money options and RSUs will vest and be cashed out at closing
- No financing condition; $155M reverse termination fee if Catalyst accepts a superior proposal
Financial Impact
$4.1B total equity value at $31.50/share cash; 28% premium to 30-day VWAP
Risk Factors
- Shareholder vote required; unaffiliated holders must approve by majority of outstanding shares
- HSR review could be extended by a Second Request
- Pre-closing operating covenants restrict Catalyst from pursuing alternative transactions
- Risk of stockholder litigation challenging the process or price
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| PREM14A Filing (Primary) | 0001193125-26-245426 |
| Document: d76493dexfilingfees.htm | 0001193125-26-245426 |
| Document: 0001193125-26-245426-index-headers.html | 0001193125-26-245426 |
| Document: 0001193125-26-245426-index.html | 0001193125-26-245426 |
| Document: 0001193125-26-245426.txt | 0001193125-26-245426 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 22, 2026 5w ago | Institutional Cluster | — | awaiting T+5 | — | — |
Jul 24, 2026 9w ago | 15-12G | $31.49 awaiting T+5 | awaiting T+5 | — | — |
Jul 17, 2026 11w ago | EFFECT | $31.49 $31.49 | · 0.00% | ▼ −0.59% | — |
Jul 15, 2026 11w ago | 25-NSE | $31.49 $31.49 | · 0.00% | ▼ −0.98% | — |
Jul 8, 2026 12w ago | 8-K | $31.47 $31.49 | ▲ +0.06% | ▲ +0.20% | — |
Jun 30, 2026 13w ago | DEFA14A | $31.44 $31.49 | ▲ +0.16% | ▼ −0.10% | — |
Jun 30, 2026 13w ago | 8-K | $31.44 $31.49 | ▲ +0.16% | ▼ −0.10% | — |
May 28, 2026 18w ago | PREM14A | $31.23 $31.28 | ▲ +0.16% | ▲ +0.45% | — |
May 12, 2026 20w ago | DEFA14A | $31.14 $31.23 | ▲ +0.29% | ▲ +0.21% | — |
May 11, 2026 20w ago | Press Release | $31.14 $31.23 | ▼ −0.29% | ▼ −0.21% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access